BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xenon Pharmaceuticals Inc. Named Company of the Year by BIOTECanada


4/22/2013 10:24:54 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

VANCOUVER, British Columbia, April 22, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada's Gold Leaf Company of the Year Award for 2013.

The prestigious Gold Leaf Awards ceremony will take place on Tuesday, April 23 at the BIO International Convention in Chicago. Several thousand guests will be in attendance, representing the global life sciences community.

"We are honored to be recognized by our national industry peers in this way," commented Simon Pimstone, Xenon's President and CEO. "The team at Xenon has worked hard to create an exciting pipeline of products and have executed on multiple partnerships with leading industry partners. One of Xenon's early discoveries forms the active ingredient of the gene therapy product Glybera®, which has recently been approved in Europe to treat lipoprotein lipase deficiency. Xenon's XEN402 analgesic product, which is partnered with Teva, will soon be entering phase 2b trials. This year, we also expect to file an investigational new drug (IND) application on our XEN701 antisense product for the treatment of anemia in renal disease patients who are erythropoietin (EPO) resistant or EPO intolerant. 2013 promises to be a very exciting year for Xenon as we continue to advance our products for rare diseases."

About Xenon Pharmaceuticals Inc. Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies for rare diseases. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Xenon Pharmaceuticals Inc.



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES